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Abstract
Anesthetics are in routine use, yet the mechanisms underlying their function are incompletely understood. Studies in vitro
demonstrate that both GABAA and NMDA receptors are modulated by anesthetics, but whole animal models have not
supported the role of these receptors as sole effectors of general anesthesia. Findings in C. elegans and in children reveal
that defects in mitochondrial complex I can cause hypersensitivity to volatile anesthetics. Here, we tested a knockout (KO)
mouse with reduced complex I function due to inactivation of the Ndufs4 gene, which encodes one of the subunits of
complex I. We tested these KO mice with two volatile and two non-volatile anesthetics. KO and wild-type (WT) mice were
anesthetized with isoflurane, halothane, propofol or ketamine at post-natal (PN) days 23 to 27, and tested for loss of
response to tail clamp (isoflurane and halothane) or loss of righting reflex (propofol and ketamine). KO mice were 2.5 - to 3-
fold more sensitive to isoflurane and halothane than WT mice. KO mice were 2-fold more sensitive to propofol but resistant
to ketamine. These changes in anesthetic sensitivity are the largest recorded in a mammal.
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Introduction
The molecular mechanisms responsible for the effects of volatile
anesthetics are far from clear. Although volatile anesthetics inhibit
excitatory synaptic transmission and enhance inhibitory signaling,
there is little agreement as to how this phenomenon occurs [1–3].
Ligand-gated ion channels initially emerged as the leading
candidates to mediate these effects. Both GABAA and NMDA
receptors were initially viewed as likely volatile anesthetic targets,
by virtue of their physiologic functions and anatomic locations
within the central nervous system (CNS) [3]. A large number of
compelling in vitro studies substantiated these hypotheses, since
volatile anesthetics could potentiate inhibitory currents through
GABAA channels, or inhibit excitatory transmission in glutama-
tergic neurons [1,4]. However, for a number of different possible
reasons, whole animal models have not supported the hypothesis
that NMDA and GABAA receptors mediate all aspects of general
anesthesia produced by volatile anesthetics [5,6]. To date the
largest change in a mammal to a volatile anesthetic is a 40%
decrease in sensitivity to halothane in a mouse that lacks a 2-pore
potassium channel, TREK-1 [7].
In a forward genetic screen in the nematode, C. elegans, we
identified a mutation, gas-1(fc21), that caused a very significant
hypersensitivity to all volatile anesthetics [8]. The gas-1 gene
encodes a highly conserved subunit of complex I of the electron
transport chain (83% similar to the human orthologue NDUFS2)
[9,10]. RNAi inhibition of most complex I subunits also increased
volatile anesthetic sensitivity [11]. Interestingly, mutations in
subunits of complex II, III, or IV did not change sensitivity of C.
elegans to volatile anesthetics, even though animals carrying these
mutations share many other phenotypes with gas-1 [12,13].
Children with defects in complex I function were hypersensitive
to sevoflurane, whereas children with defects in other steps of
electron transport within the mitochondrion were not, even
though they were indistinguishable in symptoms of mitochondrial
disease from the complex I-deficient patients [14]. Although the
data obtained from patients predicted enhanced sensitivity of other
mammals with complex I dysfunction, the sample size was low, the
genes involved were unknown, and controls were a mixed
population.
A mouse model with complex I deficiency was developed by
conditional inactivation of the Ndufs4 gene that encodes an 18 kD
subunit of complex I. This subunit is not directly involved in
electron transport, but appears to play a role in assembly or
stability of the complex [15,16]. Homozygous Ndufs4-null mice
appear neurologically normal at weaning, but by post-natal day 35
(PN35) the KO mice manifest increasing ataxia, failure to thrive,
and usually die by PN55. This strain has been established as a
model for Leigh syndrome, the most common infantile mitochon-
drial disorder. Mice with selective loss of Ndufs4 function within the
CNS have the same behavioral phenotype as the total KO mice
[16].
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Initial attempts to anesthetize KO mice using standard
conditions were often fatal. Those observations along with the
knowledge of sensitivity of worms and children with complex I
deficiencies prompted us to hypothesize that the KO animals
would be hypersensitive to volatile anesthetics. We determined the
sensitivity to anesthetics shortly after weaning (PN23 to 27), when
the animals are still behaviorally normal and before there is any
evidence of neuronal degeneration in the CNS [16]. Remarkably,
KO mice displayed the greatest hypersensitivity to volatile
anesthetics ever recorded for a mammal. This sensitivity extended
to the non-volatile GABAA facilitator and agonist, propofol [17],
but not to the NMDA antagonist, ketamine [18,19]. The
differential sensitivity to different classes of anesthetics may




This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal experiments were performed with the approval of the
Animal Care and Use Committee of the University of Washington
(IACUC #2183-02). No surgery was performed and all efforts
were made to minimize suffering.
Anesthetic sensitivity
Mice were maintained with rodent diet (5053, Picolab,
Hubbard, OR) and water available ad libitum in a vivarium with
a 12-h light-dark cycle at 22uC. The KO mice were generated by
crosses of heterozygotes on a C57Bl/6 genetic background,
genotyped by polymerase chain reaction at PN22; KO and WT
littermate controls were tested for anesthetic sensitivity during the
next week.
Mice were anesthetized with halothane or isoflurane and their
temperature was maintained by radiant heat according to the
techniques of Sonner [20,21]. Animals were between 23–27 days
old at the time of exposure to anesthetic. Failure to respond to a
non-damaging tail clamp was recorded. Responses of the same
mouse to different doses of the volatile anesthetics were measured
after 15 min of equilibration between doses. All animals were
exposed to a single anesthetic drug. Samples of isoflurane or
halothane were taken at different delivery settings and measured
by gas chromatography as described [8]. The non-volatile
anesthetics: propofol (DiprivanH, AstraZeneca, Wilmington DE,
USA) or ketamine (KetasetH, Fort Dodge, IA, USA) were injected
intra-peritoneally with drug at a concentration of 10 mcg/ul.
Animals were tested for loss of righting reflex (LORR) at 5-min
intervals following injection. Animals were kept warm on a heating
pad throughout. Animals were allowed to recover for at least 24 h
before testing again at a different dose of the same anesthetic. No
animal received more than four test doses. Animals that did not
lose righting reflex within 30 min of injection were denoted as a no
LORR.
Statistics
The effective concentration for 50% of the animals tested (EC50)
for volatile anesthetics was determined as described by Sonner et
al., using an up and down method [20]. The effective dose for 50%
of maximum effect (ED50) values for propofol and ketamine were
determined by constructing a dose-response curve for each drug
and taking the midpoint of the curve. Values for EC50s and ED50s
were compared between the WT and KO strains using GraphPad
PrismH and SigmaplotH software (T-test analysis for EC50 and
built-in dose-response curve fitting for ED50) with a modification
as described by Waud [22]. Values for EC50 and ED50 were
compared between the WT and KO strains using a Students t-test.
Significance was defined as a p,0.01. Error bars in Figure 1
represent the standard deviations of the mean. Errors for propofol
and ketamine represent Standard Errors of the mean.
Results
Ndufs4 KO mice were extremely hypersensitive to isoflurane
(Figure 1), with an EC50 that was about one third that of their WT
littermates (KO EC50= 0.4460.07%; WT EC50= 1.2360.13%).
KO mice were also hypersensitive to halothane (KO
EC50= 0.5260.11%; WT EC50= 1.2860.07%, WT) as shown
in Figure 1. No animals displayed any seizure-like activity with
exposure to the volatile anesthetics. Animals reached steady state
for their response within 5 min of volatile anesthetic exposure and
they recovered from exposure to the gases within 15 min of
breathing room air. KO and WT mice displayed vigorous
responses to tail pinch in air and at sub-anesthetics doses of
volatile anesthetics. The EC50 values of WT mice were similar to
that previously reported for the C57Bl/6 strain [20]. Animals lost
righting reflex at concentrations too low to be delivered with
standard vaporizers.
KO mice were also hypersensitive to propofol, although the shift
was not as extreme as that for the volatile agents (Figure 2). The
dose of propofol that produced LORR in the KO mice was about
one half that of their WT littermates (KO ED50= 3865 mg/kg;
WT ED50= 6766 mg/kg). The maximum effect of propofol was
observed within 5 min of injection in both the WT and KO mice
and all animals recovered righting reflex within 15 min of
injection. The ED50 for propofol in WT mice agrees with
published data [23,24].
In contrast to both the previous results, the KO animals were
strikingly resistant to the effects of ketamine (Figure 3), and were
significantly resistant to the LORR (KO ED50= 10665 mg/kg;
WT ED50 = 6964 mg/kg). The maximum effect of ketamine on
LORR was seen within 5 min of injection for both WT and KO
animals and all animals recovered by 15 min after injection. The
ketamine data for the WT animals agree with a published value of
Figure 1. EC50s for isoflurane (ISO) and halothane (HAL) to
cause immobility in response to tail pinch. Dark bars show the
EC50s for wild-type (WT) mice (n = 10, ISO; n = 6, HAL); open bars show
the values for the Ndufs4 KO mice (n = 10, ISO; n = 6, HAL). Error bars
show the standard deviations. The values for the KO animals were
significantly different from those for WT with a p,0.01.
doi:10.1371/journal.pone.0042904.g001
Mitochondrial Effects on Anesthetic Sensitivity
PLOS ONE | www.plosone.org 2 August 2012 | Volume 7 | Issue 8 | e42904
65 mg/kg [23,24]. Recovery times for all drugs were similar
between WT and KO animals.
Discussion
We report here the largest change in sensitivity to volatile
anesthetics recorded for a mammal. The ability of complex I
mutations to change response to volatile anesthetics transcends
many phyla, which implies an ancient, common mechanism of
action. The KO mice were equally hypersensitive to two volatile
anesthetics that are quite different in structure. These results are in
contrast to our results with mutations in transmembrane leak
channels that result in differential sensitivity to isoflurane and
halothane in C. elegans [25]. As we have noted previously, we
believe that mitochondrial defects affect a downstream target
relative to the leak channels, such that sensitivities to all volatile
anesthetics are affected [26].
Isoflurane and halothane both enhance GABAA receptor
signaling while antagonizing NMDA receptor signaling [17]
although it is not clear that these effects cause the anesthetized
state. Numerous structure-function experiments have shown that
GABAA receptors are targets of volatile anesthetics, using in vitro
assays. However, when putative targets that were thought to be
resistant to anesthetic action were tested in genetically engineered
mice, the responses to volatile anesthetics were insufficiently
affected [5,27–29]. Thus, the true target(s) of volatile anesthetics
remain enigmatic.
The degree/direction of changes in sensitivity of Ndusf4(KO) is
not uniform across different classes of anesthetic drugs. The KO
mice were also hypersensitive to propofol, which is known to act
primarily on GABAA receptors [17]. However, the hypersensitivity
was not as great as with the volatile anesthetics. In addition, any
explanation for the hypersensitivity of the KO animals to volatile
agents and to propofol must also account for the surprising
resistance of these animals to an NMDA antagonist, ketamine
[18,19]. Since times of onset and recovery for propofol and
ketamine were the same for WT and KO animals, pharmacoki-
netics did not play a major role in these responses; the responses
represent changes in pharmacodynamics. The observation that the
KO mice are resistant to ketamine argues against the possibility
that the KO mice manifest a general neuronal dysfunction at the
time of testing that makes them hypersensitive to all neuronal
depressants. This is in agreement with studies in a mouse model of
Alzheimer’s disease, which also demonstrated no increase in
anesthetic sensitivity despite generalized CNS depression. [30,31].
It also indicates that the targets that produce the anesthetic state
are not identical between ketamine and the other anesthetics
tested here. Ketamine anesthetic action may be unique, as it has
been suggested to involve increased activation and cortical
synchronization rather than neuronal inactivation [32]. Inhibition
of HCN1 channels has also been recently suggested as a
contributing factor in the hypnotic actions of ketamine further
indicating that ketamine function is more complicated than usually
thought [33]. The resistance to ketamine in these mice raises an
intriguing question as to whether similar changes might be present
in humans and may suggest future studies.
How can mitochondrial dysfunction cause extreme hypersen-
sitivity to volatile anesthetics and propofol, and why are defects in
complex I function so important? Complex I is responsible for over
half of the electron transport necessary to generate the mitochon-
drial membrane potential and drive ATP synthesis [34]. The
mitochondrial TCA cycle generates glutamate and the precursors
of GABA and, while a small part of total energy requirements, the
glutamate/glutamine cycle between neurons and glia is dependent
on glycolysis and oxidative phosphorylation [35]. Complex I also
has the potential to generate reactive oxygen species (ROS), which
can result in deleterious oxidation events and/or serve as a critical
signaling molecule, when not functioning optimally [34]. Thus,
there are many possible ways that loss of complex I might cause
hypersensitivity to volatile anesthetics. Most notable is the finding
that presynaptic function in glutamatergic neurons is extremely
sensitive to complex I function [36].
It is possible that anesthetic sensitivity of the KO mice (as well as
C. elegans and children) with complex I deficiency is due to the
direct actions of these compounds on defective complex I [37],
Figure 2. The dose response curves for WT and Ndufs4 KO mice
for LORR after intraperitoneal propofol. Dose-response curves
were generated using the percentage of mice that presented LORR at
the measured concentrations (n = 5–7 per group for each injection
dose). The values for the KO animals were significantly different from
those for WT (p,0.01).
doi:10.1371/journal.pone.0042904.g002
Figure 3. The dose response curves for WT and Ndufs4 KO mice
for LORR after given intraperitoneal ketamine. Dose-response
curves were generated using the percentage of mice that presented
LORR at the measured concentrations (n = 5–7 per group for each
injection dose). The values for the KO animals were significantly
different from those for WT (p,0.01).
doi:10.1371/journal.pone.0042904.g003
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further inhibiting its activity and resulting in the inability to
maintain ATP production and/or essential signaling necessary to
maintain neuronal activity. Xi et al. [37] noted that several
mitochondrial proteins bind halothane, including three from
complex I, consistent with the possibility that complex I may be a
direct anesthetic target. In both worms and in mammals,
movement of electrons through complex I is clearly the most
sensitive step within the mitochondrial respiratory chain to
disruption by volatile anesthetics [9,38,39] whereas defects in
respiratory complexes II, III, and IV do not affect anesthetic
sensitivity [12–14,40].
An alternative idea is that anesthetics act primarily on ion
channels as is generally hypothesized [6,17,35], but select
populations of neurons within the CNS may depend on optimal
complex I function to maintain neuronal activity [34]. Assuming
that volatile anesthetics work by altering synaptic transmission in
some specific areas of the CNS, it may be that the animal is able to
match ATP supply to demand in most of the CNS, but has
insufficient ATP to support synaptic transmission by some crucial
neurons. Thus, if those neurons were already compromised due to
complex I mutations and consequently functioning at maximum
capacity, then modulation of ion currents by anesthetics could
selectively compromise their ability to function adequately.
Although many authors hypothesize that anesthetics act
diffusely throughout the CNS, others attribute their actions to
specific brain regions; for example, a portion of the rat brainstem
has been dubbed the ‘‘mesopontine tegmental anesthesia area’’
since injection of GABAA receptor agonists into this region
produces anesthesia [41–44]. The central medial thalamic region
of the rat brain has also been shown to be as crucial to maintaining
consciousness [44]. However, considerable controversy still
surrounds the putative location in the brain for producing the
anesthetic state. The KO mice display progressive gliosis and
eventually neurodegeneration in specific brain regions; primarily
the olfactory bulb, vestibular nucleus, posterior lobes of the
cerebellum and deep cerebellar nuclei. However, some other brain
regions are without obvious gliosis, for example, the pre-Bo¨tzinger
complex, yet are also affected by the mitochondrial defect [16,45].
Consequently, we assume that Ndfus4 deficiency does not affect all
neurons equally. The differences in sensitivity to loss of Ndufs4
could be attributable to differences in (a) intrinsic activity of the
neurons, (b) extent of activation in response to changing
conditions, or (c) regulation of complex I, for example, by
phosphorylation.
It may be possible to identify brain region(s) and neuronal
type(s) where Ndufs4 functions to maintain anesthetic sensitivity.
Because the Ndufs4 allele in our KO mice can be inactivated by
Cre recombinase, it is possible to use Cre-expressing viruses or
specific Cre-driver lines of mice to selectively inactivate Ndufs4 in
specific cell types or brain regions. Alternatively, it is possible to
restore Ndufs4 function to specific cells or brain regions in KO
mice. These approaches were used to demonstrate that the
vestibular nucleus of KO mice is selectively compromised leading
to fatal breathing abnormalities [45]. An additional challenge will
be to ascertain whether complex I dysfunction indirectly facilitates
anesthetic sensitivity or whether volatile anesthetics interfere with
complex I function to directly control sensitivity.
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